A role for cAMP-driven transactivation of EGFR in cancer aggressiveness - Therapeutic implications

Medical Hypotheses

Volumn 83, Issue 2, 2014, Pages 142-147

  McCarty, Mark F ^a  

^a Catalytic Longevity   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; CYCLOOXYGENASE 2; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PTGS2 PROTEIN, HUMAN;

ADRENERGIC SYSTEM; BIOLOGICAL MODEL; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR INVASION;

ADENYLATE CYCLASE; CYCLIC AMP; CYCLOOXYGENASE 2; HUMANS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM; TRANSCRIPTIONAL ACTIVATION;

EID: 84903639847     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.05.009     Document Type: Article

References (136)

1. Schuller H.M., Cekanova M. NNK-induced hamster lung adenocarcinomas over-express beta2-adrenergic and EGFR signaling pathways. Lung Cancer 2005, 49(1):35-45.
2. Kim J., Eckhart A.D., Eguchi S., Koch W.J. Beta-adrenergic receptor-mediated DNA synthesis in cardiac fibroblasts is dependent on transactivation of the epidermal growth factor receptor and subsequent activation of extracellular signal-regulated kinases. J Biol Chem 2002, 277(35):32116-32123.
3. Maudsley S., Pierce K.L., Zamah A.M., et al. The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 2000, 275(13):9572-9580.
4. Slomiany B.L., Slomiany A. Src-kinase-dependent epidermal growth factor receptor transactivation in salivary mucin secretion in response to beta-adrenergic G-protein-coupled receptor activation. Inflammopharmacology 2004, 12(3):233-245.
5. Slomiany B.L., Slomiany A. Gastric mucin secretion in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation. J Physiol Pharmacol 2005, 56(2):247-258.
6. Drube S., Stirnweiss J., Valkova C., Liebmann C. Ligand-independent and EGF receptor-supported transactivation: lessons from beta2-adrenergic receptor signalling. Cell Signal 2006, 18(10):1633-1646.
7. Chen H., Ma N., Xia J., Liu J., Xu Z. Beta2-Adrenergic receptor-induced transactivation of epidermal growth factor receptor and platelet-derived growth factor receptor via Src kinase promotes rat cardiomyocyte survival. Cell Biol Int 2012, 36(3):237-244.
8. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002, 8(3):289-293.
9. Buchanan F.G., Wang D., Bargiacchi F., DuBois R.N. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003, 278(37):35451-35457.
10. Ding Y.B., Shi R.H., Tong J.D., et al. PGE2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system. Exp Oncol 2005, 27(2):108-113.
11. Mendez M., LaPointe M.C. PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation. Am J Physiol Heart Circ Physiol 2005, 288(5):H2111-H2117.
12. Donnini S., Finetti F., Solito R., et al. EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J 2007, 21(10):2418-2430.
13. Dajani O.F., Meisdalen K., Guren T.K., et al. Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes. J Cell Physiol 2008, 214(2):371-380.
14. Banu N., Buda A., Chell S., et al. Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy. Cell Prolif 2007, 40(5):768-779.
15. Wu W.K., Sung J.J., Lee C.W., Yu J., Cho C.H. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett 2010, 295(1):7-16.
16. Finetti F., Terzuoli E., Bocci E., et al. Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis. PLoS One 2012, 7(7):e40576.
17. Tveteraas I.H., Muller K.M., Aasrum M., et al. Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells. J Exp Clin Cancer Res 2012, 31:72.
18. Evaul K., Hammes S.R. Cross-talk between G protein-coupled and epidermal growth factor receptors regulates gonadotropin-mediated steroidogenesis in Leydig cells. J Biol Chem 2008, 283(41):27525-27533.
19. Bertelsen L.S., Barrett K.E., Keely S.J. Gs protein-coupled receptor agonists induce transactivation of the epidermal growth factor receptor in T84 cells: implications for epithelial secretory responses. J Biol Chem 2004, 279(8):6271-6279.
20. Etkovitz N., Tirosh Y., Chazan R., et al. Bovine sperm acrosome reaction induced by G-protein-coupled receptor agonists is mediated by epidermal growth factor receptor transactivation. Dev Biol 2009, 334(2):447-457.
21. Breitbart H., Etkovitz N. Role and regulation of EGFR in actin remodeling in sperm capacitation and the acrosome reaction. Asian J Androl 2011, 13(1):106-110.
22. Borland G., Smith B.O., Yarwood S.J. EPAC proteins transduce diverse cellular actions of cAMP. Br J Pharmacol 2009, 158(1):70-86.
23. Zhang D., Ma Q.Y., Hu H.T., Zhang M. Beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkappaB and AP-1. Cancer Biol Ther 2010, 10(1):19-29.
24. Yang E.V., Donovan E.L., Benson D.M., Glaser R. VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine. Brain Behav Immun 2008, 22(3):318-323.
25. Landen C.N., Lin Y.G., Armaiz Pena G.N., et al. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 2007, 67(21):10389-10396.
26. Shahzad M.M., Arevalo J.M., Armaiz-Pena G.N., et al. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 2010, 285(46):35462-35470.
27. Yang E.V., Sood A.K., Chen M., et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006, 66(21):10357-10364.
28. Sood A.K., Bhatty R., Kamat A.A., et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006, 12(2):369-375.
29. Liao X., Che X., Zhao W., et al. Effects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitro. Radiat Oncol 2010, 5:98.
30. Valles S.L., Benlloch M., Rodriguez M.L., et al. Stress hormones promote growth of B16-F10 melanoma metastases: an interleukin 6- and glutathione-dependent mechanism. J Transl Med 2013, 11:72.
31. Moretti S., Massi D., Farini V., et al. Beta-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. Lab Invest 2013, 93(3):279-290.
32. Schuller H.M., Al-Wadei H.A., Ullah M.F., Plummer H.K. Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention. Carcinogenesis 2012, 33(1):191-196.
33. Shi M., Yang Z., Hu M., et al. Catecholamine-induced beta2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression. J Immunol 2013, 190(11):5600-5608.
34. Xin X., Majumder M., Girish G.V., Mohindra V., Maruyama T., Lala P.K. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest 2012, 92(8):1115-1128.
35. Jain S., Chakraborty G., Raja R., Kale S., Kundu G.C. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008, 68(19):7750-7759.
36. Wang X., Klein R.D. Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway. Mol Carcinog 2007, 46(11):912-923.
37. Chun K.S., Langenbach R. The prostaglandin E2 receptor, EP2, regulates survivin expression via an EGFR/STAT3 pathway in UVB-exposed mouse skin. Mol Carcinog 2011, 50(6):439-448.
38. Rasmuson A., Kock A., Fuskevag O.M., et al. Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS One 2012, 7(1):e29331.
39. Armaiz-Pena G.N., Allen J.K., Cruz A., et al. Src activation by beta-adrenoreceptors is a key switch for tumour metastasis. Nat Commun 2013, 4:1403.
40. Ciardiello F., Tortora G. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Clin Cancer Res 1998, 4(4):821-828.
41. Tortora G., Pepe S., Bianco C., et al. The RI alpha subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. Oncogene 1994, 9(11):3233-3240.
42. Cho-Chung Y.S. Antisense DNA toward type I protein kinase A produces sustained inhibition of tumor growth. Proc Assoc Am Physicians 1997, 109(1):23-32.
43. Cho-Chung Y.S., Nesterova M., Pepe S., et al. Antisense DNA-targeting protein kinase A-RIA subunit: a novel approach to cancer treatment. Front Biosci 1999, 4:D898-D907.
44. Neary C.L., Nesterova M., Cho Y.S., Cheadle C., Becker K.G., Cho-Chung Y.S. Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion. Oncogene 2004, 23(54):8847-8856.
45. Tortora G., Damiano V., Bianco C., et al. The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene 1997, 14(8):923-928.
46. Stork P.J., Schmitt J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002, 12(6):258-266.
47. Yoo S., Lee Y.G., Kim J.H., et al. Cyclic adenosine monophosphate (cAMP)-induced histone hyperacetylation contributes to its antiproliferative and differentiation-inducing activities. Z Naturforsch C 2012, 67(3-4):222-232.
48. Yan L., Herrmann V., Hofer J.K., Insel P.A. Beta-adrenergic receptor/cAMP-mediated signaling and apoptosis of S49 lymphoma cells. Am J Physiol Cell Physiol 2000, 279(5):C1665-C1674.
49. Ogawa R., Streiff M.B., Bugayenko A., Kato G.J. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. Blood 2002, 99(9):3390-3397.
50. Ali S., El-Rayes B.F., Sarkar F.H., Philip P.A. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 2005, 4(12):1943-1951.
51. Buchanan F.G., Holla V., Katkuri S., Matta P., DuBois R.N. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res 2007, 67(19):9380-9388.
52. Gadgeel S.M., Ali S., Philip P.A., Ahmed F., Wozniak A., Sarkar F.H. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. Cancer 2007, 110(12):2775-2784.
53. Kao J., Genden E.M., Chen C.T., et al. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer 2011, 117(14):3173-3181.
54. Fu S., Rivera M., Ko E.C., et al. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 as a novel approach to enhance radiotherapy. J Cell Sci Ther 2011, 1(2). pii:S1-002.
55. Shan T., Ma Q., Zhang D., et al. Beta2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Eur J Pharmacol 2011, 665(1-3):1-7.
56. Lin J., Wu H., Shi H., Pan W., Yu H., Zhu J. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer. PLoS One 2013, 8(10):e76169.
57. Chen H.X., Marshall J.L., Ness E., et al. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin Cancer Res 2000, 6(4):1259-1266.
58. Agrawal S., Kandimalla E.R., Yu D., et al. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. Int J Oncol 2002, 21(1):65-72.
59. Goel S., Desai K., Macapinlac M., et al. A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. Invest New Drugs 2006, 24(2):125-134.
60. Rothwell P.M., Wilson M., Elwin C.E., et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010, 376(9754):1741-1750.
61. Rothwell P.M., Fowkes F.G., Belch J.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377(9759):31-41.
62. Algra A.M., Rothwell P.M. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012, 13(5):518-527.
63. Ghosh N., Chaki R., Mandal V., Mandal S.C. COX-2 as a target for cancer chemotherapy. Pharmacol Rep 2010, 62(2):233-244.
64. Groen H.J., Sietsma H., Vincent A., et al. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol 2011, 29(32):4320-4326.
65. James N.D., Sydes M.R., Mason M.D., et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 2012, 13(5):549-558.
66. Koch A., Bergman B., Holmberg E., et al. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer 2011, 47(10):1546-1555.
67. Reyners A.K., drete M.L., Erdkamp F.L., et al. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Ann Oncol 2012, 23(11):2896-2902.
68. Sabichi A.L., Lee J.J., Grossman H.B., et al. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) 2011, 4(10):1580-1589.
69. Rothwell P.M., Wilson M., Price J.F., Belch J.F., Meade T.W., Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, 379(9826):1591-1601.
70. Spiegel D. Minding the body: psychotherapy and cancer survival. Br J Health Psychol 2013, [Epub ahead of print].
71. Cataldo J.K., Dubey S., Prochaska J.J. Smoking cessation: an integral part of lung cancer treatment. Oncology 2010, 78(5-6):289-301.
72. Ioffe Y.J., Elmore R.G., Karlan B.Y., Li A.J. Effect of cigarette smoking on epithelial ovarian cancer survival. J Reprod Med 2010, 55(7-8):346-350.
73. Braithwaite D., Izano M., Moore D.H., et al. Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review. Breast Cancer Res Treat 2012, 136(2):521-533.
74. Wu I.C., Wu C.C., Lu C.Y., et al. Substance use (alcohol, areca nut and cigarette) is associated with poor prognosis of esophageal squamous cell carcinoma. PLoS One 2013, 8(2):e55834.
75. Crivelli J.J., Xylinas E., Kluth L.A., Rieken M., Rink M., Shariat S.F. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol 2014, 65(4):742-754.
76. Han M.A., Kim Y.W., Choi I.J., et al. Association of smoking history with cancer recurrence and survival in stage III-IV male gastric cancer patients. Cancer Epidemiol Biomarkers Prev 2013, 22(10):1805-1812.
77. Liu D., Li Q., Yang Z., et al. Association of body mass index and smoking on outcome of Chinese patients with colorectal cancer. World J Surg Oncol 2013, 11(1):271.
78. Pelucchi C., Galeone C., Polesel J., et al. Smoking and body mass index and survival in pancreatic cancer patients. Pancreas 2014, 43(1):47-52.
79. Chisholm K.M., Chang K.W., Truong M.T., Kwok S., West R.B., Heerema-McKenney A.E. Beta-Adrenergic receptor expression in vascular tumors. Mod Pathol 2012, 25(11):1446-1451.
80. Kassahun W.T., Guenl B., Ungemach F.R., Jonas S., Abraham G. Expression and functional coupling of liver beta2 - adrenoceptors in the human hepatocellular carcinoma. Pharmacology 2012, 89(5-6):313-320.
81. Perez-Sayans M., Somoza-Martin J.M., Barros-Angueira F., Diz P.G., Gandara Rey J.M., Garcia-Garcia A. Beta-adrenergic receptors in cancer: therapeutic implications. Oncol Res 2010, 19(1):45-54.
82. Shang Z.J., Liu K., Liang D.F. Expression of beta2-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 2009, 38(4):371-376.
83. Ramberg H., Eide T., Krobert K.A., et al. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate 2008, 68(10):1133-1142.
84. Schuller H.M. Neurotransmitter receptor-mediated signaling pathways as modulators of carcinogenesis. Prog Exp Tumor Res 2007, 39:45-63.
85. Fitzgerald P.J. Is norepinephrine an etiological factor in some types of cancer?. Int J Cancer 2009, 124(2):257-263.
86. Ji Y., Chen S., Xiao X., Zheng S., Li K. Beta-blockers: a novel class of antitumor agents. Onco Targets Ther 2012, 5:391-401.
87. Tang J., Li Z., Lu L., Cho C.H. Beta-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol 2013, 6 PTB:533-542.
88. Palm D., Lang K., Niggemann B., et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006, 118(11):2744-2749.
89. Lee J.W., Shahzad M.M., Lin Y.G., et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 2009, 15(8):2695-2702.
90. Sloan E.K., Priceman S.J., Cox B.F., et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010, 70(18):7042-7052.
91. Hassan S., Karpova Y., Baiz D., et al. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest 2013, 123(2):874-886.
92. Lin X., Luo K., Lv Z., Huang J. Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice. Hepatogastroenterology 2012, 59(114):584-588.
93. Wong H.P., Yu L., Lam E.K., Tai E.K., Wu W.K., Cho C.H. Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol Sci 2007, 97(2):279-287.
94. Lin Q., Wang F., Yang R., Zheng X., Gao H., Zhang P. Effect of chronic restraint stress on human colorectal carcinoma growth in mice. PLoS One 2013, 8(4):e61435.
95. Lutgendorf S.K., Cole S., Costanzo E., et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003, 9(12):4514-4521.
96. Guo K., Ma Q., Li J., et al. Interaction of the sympathetic nerve with pancreatic cancer cells promotes perineural invasion through the activation of STAT3 signaling. Mol Cancer Ther 2013, 12(3):264-273.
97. Al-Wadei H.A., Al-Wadei M.H., Schuller H.M. Cooperative regulation of non-small cell lung carcinoma by nicotinic and beta-adrenergic receptors: a novel target for intervention. PLoS One 2012, 7(1):e29915.
98. Al-Wadei M.H., Al-Wadei H.A., Schuller H.M. Pancreatic cancer cells and normal pancreatic duct epithelial cells express an autocrine catecholamine loop that is activated by nicotinic acetylcholine receptors alpha3, alpha5, and alpha7. Mol Cancer Res 2012, 10(2):239-249.
99. Shin V.Y., Jin H.C., Ng E.K., et al. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: Involvement of nicotinic acetylcholine receptor (nAChR) and beta-adrenergic receptor signaling pathways. Toxicol Appl Pharmacol 2008, 233(2):254-261.
100. Pasquier E., Street J., Pouchy C., et al. Beta-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer 2013, 108(12):2485-2494.
101. Stiles J.M., Amaya C., Rains S., et al. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PLoS One 2013, 8(3):e60021.
102. Wolter N.E., Wolter J.K., Enepekides D.J., Irwin M.S. Propranolol as a novel adjunctive treatment for head and neck squamous cell carcinoma. J Otolaryngol Head Neck Surg 2012, 41(5):334-344.
103. Pasquier E., Ciccolini J., Carre M., et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2011, 2(10):797-809.
104. Schuller H.M. Beta-adrenergic signaling, a novel target for cancer therapy?. Oncotarget 2010, 1(7):466-469.
105. Hicks B.M., Murray L.J., Powe D.G., Hughes C.M., Cardwell C.R. Beta-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort. Ann Oncol 2013, 24(12):3100-3106.
106. Friedman G.D., Udaltsova N., Habel L.A. Norepinephrine antagonists and cancer risk. Int J Cancer 2011, 128(3):737-738.
107. Monami M., Filippi L., Ungar A., et al. Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. Curr Med Res Opin 2013, 29(4):369-378.
108. Nkontchou G., Aout M., Mahmoudi A., et al. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. Cancer Prev Res (Phila) 2012, 5(8):1007-1014.
109. De G.V., Gandini S., Grazzini M., Benemei S., Marchionni N., Geppetti P. Beta-blockers: a new and emerging treatment for melanoma. Recenti Prog Med 2012, 103(1):11-16.
110. Powe D.G., Voss M.J., Zanker K.S., et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010, 1(7):628-638.
111. Barron T.I., Connolly R.M., Sharp L., Bennett K., Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 2011, 29(19):2635-2644.
112. Melhem-Bertrandt A., Chavez-Macgregor M., Lei X., et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011, 29(19):2645-2652.
113. De G.V., Gandini S., Grazzini M., Benemei S., Marchionni N., Geppetti P. Effect of beta-Blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. Mayo Clin Proc 2013, 88(11):1196-1203.
114. Watkins, J et al. Improved outcomes with beta blocker use in epithelial ovarian cancer patients. Society of Gynecologic Oncology - 2013 Conference, Abstract 75. 2013. Ref Type: Abstract.
115. Persky V., Dyer A.R., Leonas J., et al. Heart rate: a risk factor for cancer?. Am J Epidemiol 1981, 114(4):477-487.
116. Wannamethee G., Shaper A.G., MacFarlane P.W. Heart rate, physical activity, and mortality from cancer and other noncardiovascular diseases. Am J Epidemiol 1993, 137(7):735-748.
117. Thomas F., Guize L., Bean K., Benetos A. Pulse pressure and heart rate: independent risk factors for cancer?. J Clin Epidemiol 2001, 54(7):735-740.
118. Jouven X., Escolano S., Celermajer D., et al. Heart rate and risk of cancer death in healthy men. PLoS One 2011, 6(8):e21310.
119. Facchini F.S., Stoohs R.A., Reaven G.M. Enhanced sympathetic nervous system activity. The linchpin between insulin resistance, hyperinsulinemia, and heart rate. Am J Hypertens 1996, 9(10 Pt 1):1013-1017.
120. Omvik P. How smoking affects blood pressure. Blood press 1996, 5(2):71-77.
121. Yamaguchi J., Hozawa A., Ohkubo T., et al. Factors affecting home-measured resting heart rate in the general population: the Ohasama study. Am J Hypertens 2005, 18(9 Pt 1):1218-1225.
122. Esposito K., Chiodini P., Colao A., Lenzi A., Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012, 35(11):2402-2411.
123. Ferguson R.D., Gallagher E.J., Scheinman E.J., Damouni R., LeRoith D. The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer. Vitam Horm 2013, 93:51-98.
124. Clague J., Bernstein L. Physical activity and cancer. Curr Oncol Rep 2012, 14(6):550-558.
125. Fitzpatrick A.L., Daling J.R., Furberg C.D., Kronmal R.A., Weissfeld J.L. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 2001, 11(8):534-542.
126. Gann P.H., Daviglus M.L., Dyer A.R., Stamler J. Heart rate and prostate cancer mortality: results of a prospective analysis. Cancer Epidemiol Biomarkers Prev 1995, 4(6):611-616.
127. Friedman G.D. Blood pressure and heart rate: no evidence for a positive association with prostate cancer. Ann Epidemiol 1997, 7(7):486-489.
128. James G.D., Berge-Landry H.H., Valdimarsdottir H.B., Montgomery G.H., Bovbjerg D.H. Urinary catecholamine levels in daily life are elevated in women at familial risk of breast cancer. Psychoneuroendocrinology 2004, 29(7):831-838.
129. Glasner A., Avraham R., Rosenne E., et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 2010, 184(5):2449-2457.
130. Al-Wadei H.A., Plummer H.K., Ullah M.F., Unger B., Brody J.R., Schuller H.M. Social stress promotes and gamma-aminobutyric acid inhibits tumor growth in mouse models of non-small cell lung cancer. Cancer Prev Res (Phila) 2012, 5(2):189-196.
131. Schuller H.M., Al-Wadei H.A. Neurotransmitter receptors as central regulators of pancreatic cancer. Future Oncol 2010, 6(2):221-228.
132. Al-Wadei H.A., Plummer H.K., Schuller H.M. Nicotine stimulates pancreatic cancer xenografts by systemic increase in stress neurotransmitters and suppression of the inhibitory neurotransmitter gamma-aminobutyric acid. Carcinogenesis 2009, 30(3):506-511.
133. Al-Wadei H.A., Al-Wadei M.H., Ullah M.F., Schuller H.M. Celecoxib and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed mice. PLoS One 2012, 7(8):e43376.
134. Lodewyks C., Rodriguez J., Yan J., et al. GABA-B receptor activation inhibits the in vitro migration of malignant hepatocytes. Can J Physiol Pharmacol 2011, 89(6):393-400.
135. Fava G., Marucci L., Glaser S., et al. Gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res 2005, 65(24):11437-11446.
136. Opolski A., Mazurkiewicz M., Wietrzyk J., Kleinrok Z., Radzikowski C. The role of GABA-ergic system in human mammary gland pathology and in growth of transplantable murine mammary cancer. J Exp Clin Cancer Res 2000, 19(3):383-390.